Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection

70Citations
Citations of this article
56Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The immunological and virological impact of short-term treatment initiated during acute human immunodeficiency virus type 1 (HIV-1) infection was assessed prospectively in 20 subjects, 12 of whom initiated highly active antiretroviral therapy (HAART) for 24 weeks and then terminated treatment. Treatment resulted in suppression of viremia, an increase in the CD4+ T cell count, enhanced differentiation of HIV-1-specific CD8+ T cells from effector memory to effector cells at week 24 of HAART, and significantly higher virus-specific interferon-γ+ CD8+ T cell responses after viral rebound (at week 48). However, despite these immunological changes, no differences in viremia or in the CD4+ T cell count were found 6 months after HAART was stopped, when treated subjects were compared with untreated subjects. © 2006 by the Infectious Diseases Society of America. All rights reserved.

Cite

CITATION STYLE

APA

Streeck, H., Jessen, H., Alter, G., Teigen, N., Waring, M. T., Jessen, A., … Altfeld, M. (2006). Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. Journal of Infectious Diseases, 194(6), 734–739. https://doi.org/10.1086/503811

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free